Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

A Multicenter, Open Label, Multiple Dose, Parallel Group Investigation Of The Long-term Safety, Tolerability, Reactogenicity, Pharmacokinetics And Pharmacodynamics Of Aab-001 Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer's Disease

This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US). Subjects will receive weekly injections of bapineuzumab for 3 years (156 doses). One dosage level will be included: 5 mg/week. All subjects will receive active treatment (bapineuzumab) and no subjects will receive placebo.

Inclusion Criteria:

• Diagnosis of probable Alzheimer disease
• Completed preceding double-blind study (3133L1-2203 US)
• MMSE score > 9.

Exclusion Criteria:

• Significant brain MRI abnormalities
• Clinically important psychiatric symptoms
• History of stroke